The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. This year’s metric has recorded a Price decrease of -56.55%. However, over the past six months, we’ve seen a stronger performance of -44.92%. The price of EBS leaped by -4.86% over the last 30 days. And in the last five days, it has fallen by -20.76%.
The stock price for Emergent Biosolutions Inc (EBS) currently stands at $6.07. The stock experienced a substantial increase in the last session, hitting $15.0 after starting at $6.07. The stock’s lowest price was $12.0 before closing at $6.5.
Emergent Biosolutions Inc saw a rather unpredictable run in, in terms of market performance.
52-week price history of EBS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Emergent Biosolutions Inc’s current trading price is -59.80% away from its 52-week high, while its distance from the 52-week low is 51.00%. The stock’s price range during this period has varied between$4.02 and $15.10. The Emergent Biosolutions Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.57 million for the day, a figure considerably higher than their average daily volume of 1.27 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Emergent Biosolutions Inc (EBS) has experienced a quarterly rise of 11.38% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 329.47M and boasts a workforce of 900 employees.
Emergent Biosolutions Inc: Analysts’ Ratings Unveiled
As of right now, 1 analyst is rating Emergent Biosolutions Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
EBS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for EBS stands at 1.22. Similarly, the long-term debt-to-equity ratio is also 1.21.
EBS Stock Stochastic Average
As of today, Emergent Biosolutions Inc’s raw stochastic average for the last 50 days stands at 95.48%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 90.48%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 91.94% and 93.45%, respectively.
